aray-ex1052_285.htm



Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.

 

Exhibit 10.52

Amendment No. 4 TO CREDIT AND SECURITY AGREEMENT (REVOLVER) 

THIS AMENDMENT NO. 4 TO CREDIT AND SECURITY AGREEMENT (this “Amendment”) is made as of this 30th day of May, 2019, by and among MIDCAP FUNDING IV TRUST, a Delaware statutory trust (as successor by assignment from MidCap Funding X Trust, as successor by assignment from MidCap Funding IV Trust, as successor by assignment from MidCap Financial Trust), individually as a Lender, and as Agent, and the financial institutions or other entities from time to time parties hereto, each as a Lender., the lenders (individually, each a “Lender” and collectively, the “Lenders”) party to the Credit Agreement (as defined below), ACCURAY INCORPORATED, a Delaware corporation (“Accuray” or “Borrower Representative”), TOMOTHERAPY INCORPORATED, a Wisconsin corporation, and any additional borrower that may hereafter be added to this Agreement (collectively, “Other Borrowers” and, together with Borrower Representative, each individually as a “Borrower”, and collectively as “Borrowers”).

RECITALS

A.        Borrowers, Agent and the Lenders are party to that certain Credit and Security Agreement dated as of June 14, 2017, as previously amended and modified (as amended hereby, and as may be further amended, supplemented, restated or otherwise modified from time to time, the “Credit Agreement”), pursuant to which Lenders agreed to make available to Borrowers a revolving loan facility in the maximum principal amount of $32,000,000 at any time outstanding.  Capitalized terms used but not defined in this Amendment shall have the meanings that are set forth in the Credit Agreement, as amended hereby.

B.        Borrowers have requested certain amendments to the Credit Agreement all as set forth herein.

C.        The parties now agree to amend and modify the Credit Agreement all in accordance with the terms and conditions set forth below.

NOW, THEREFORE, in consideration of the foregoing, the terms and conditions set forth in this Amendment, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Agent, Lenders and Borrowers hereby agree as follows:

1.Specific Amendments to Credit Agreement.

(a)New definitions of Fourth Amendment Effective Date and Market Withdrawal are added to Section 1.1 of the Credit Agreement in alphabetical order to read as follows:

““Fourth Amendment Effective Date” means May 30, 2019.”

““Market Withdrawal” means a Person’s removal from any market or correction of a Product that involves a minor violation that would not be subject to legal action by the FDA or that involves no violation.”

 



 

(b)The definitions of Applicable Margin and Commitment Expiry Date in Section 1.1 of the Credit Agreement are hereby deleted in their entirety and restated to read as follows:

““Applicable Margin” means with respect to Revolving Loans and all other Obligations three and one-half percent (3.50%).”

““Commitment Expiry Date” means the date that is five (5) years following the Fourth Amendment Effective Date (the “Stated Commitment Expiry Date”); provided, however, that if, as of the Early Maturity Date with respect to any series of notes included as Convertible Notes Debt (collectively, “Convertible Notes”), a Convertible Notes Event with respect to such series of Convertible Notes has not occurred, then the Commitment Expiry Date shall be the Early Maturity Date with respect to such series of Convertible Notes (the occurrence of the event described in this proviso, an “Early Maturity Event”); provided further, however, that if a Convertible Notes Event with respect to all of such series of Convertible Notes has not occurred prior to the Early Maturity Date with respect to such series of Convertible Notes, but as of such Early Maturity Date with respect to such series of Convertible Notes the Liquidity Condition is satisfied with respect to the portion of such series that is not subject to a Convertible Notes Event, then (a) an Early Maturity Event shall not occur and (b) the Commitment Expiry Date shall continue to be the Stated Commitment Expiry Date unless, as of any time (the date on which such time occurs, the “Accelerated Commitment Expiry Date”) on or after the Early Maturity Date with respect to such series of  Convertible Notes when a Convertible Notes Event with respect to such series of Convertible Notes has not occurred, (y) the Liquidity Condition with respect to such series of Convertible Notes is not satisfied, in which event the Commitment Expiry Date shall be the Accelerated Commitment Expiry Date or (z) an Early Maturity Event occurs with respect to any other series of Convertible Notes and Borrowers have not caused the Commitment Expiry Date to remain the Stated Commitment Expiry Date in accordance with the second proviso of this definition.”

(c)Section 2.2(g) of the Credit Agreement is hereby deleted in its entirety and restated to read as follows:

“(g)Deferred Revolving Loan Origination Fee.  If Lenders’ funding obligations in respect of the Revolving Loan Commitment under this Agreement terminate for any reason (whether by voluntary termination by Borrowers, by reason of the occurrence of an Event of Default or otherwise) other than as a result of a refinancing of 100% of the Loans by Agent and all Lenders prior to the Commitment Expiry Date and other than the reduction in the Revolving Loan Commitment on the First Amendment Effective Date, Borrowers shall pay to Agent on the date of such termination, for the benefit of all Lenders committed to make Revolving Loans on the Closing Date, a fee as compensation for the costs of such Lenders being prepared to make funds available to Borrowers under this Agreement, equal to an amount determined by multiplying the Revolving Loan Commitment terminated by the following applicable percentage amount:  three percent (3%) for the first year following the Fourth Amendment Effective Date, two percent (2%) for the second year following the Fourth Amendment Effective Date, and one percent (1%) thereafter.  All fees payable pursuant to this paragraph shall be deemed fully earned and non-refundable as of the Closing Date.”

 

2



 

(d)Section 3.25(d) of the Credit Agreement is hereby deleted in its entirety and restated to read as follows:

“(d)There have been no adverse clinical test results which have or could reasonably be expected to have a materially adverse impact on Accuray or any of its Subsidiaries, and there have been no Product recalls or voluntary Product withdrawals from any market (other than (i) those recalls or voluntary withdrawals disclosed on the Compliance Certificate delivered for the calendar month ending April 30, 2019 (provided that no disclosure shall be deemed to waive any Default or Event of Default that may result from such withdrawal) and (ii) Market Withdrawals).”

(e)Schedule 9.2 to the Credit Agreement is hereby deleted in its entirety and restated with Schedule 9.2 attached hereto.

2.Reaffirmation of Security Interest.  Each Borrower hereby expressly acknowledges and agrees that all Liens granted under the Financing Documents extend to and cover all of the obligations of Borrowers and any other Credit Party to Agent and the Lenders, now existing or hereafter arising including, without limitation, those arising in connection with the Credit Agreement, as amended by this Amendment, upon the terms set forth in the Credit Agreement, all of which Liens are hereby ratified, reaffirmed, confirmed and approved.

3.Enforceability.  This Amendment constitutes the legal, valid and binding obligation of Borrowers, and is enforceable against Borrowers in accordance with its terms, except as the enforceability thereof may be limited by bankruptcy, insolvency or other similar laws relating to the enforcement of creditors’ rights generally and by general equitable principles.  Each of the agreements, documents and instruments executed in connection herewith to which a Borrower is a party constitutes the legal, valid and binding obligation of such Borrower, and is enforceable against such Borrower in accordance with its terms, except as the enforceability thereof may be limited by bankruptcy, insolvency or other similar laws relating to the enforcement of creditors’ rights generally and by general equitable principles.

4.Confirmation of Representations and Warranties.  Each Credit Party represents and warrants to Agent and Lenders that, before and after giving effect to this Amendment:

(a)the representations and warranties of each Credit Party contained in the Financing Documents are true, correct and complete in all material respects (or, if such representation or warranty is, by its terms, qualified by materiality, in all respects) on and as of the date hereof, except to the extent that any such representation or warranty relates to a specific date in which case such representation or warranty is true, correct and complete in all material respects (or, if such representation or warranty is, by its terms, qualified by materiality, in all respects) as of such earlier date.

 

3



 

(b)The execution and delivery by each Credit Party of this Amendment and the performance by it of the transactions herein contemplated (i) are and will be within its powers, (ii) have been authorized by all necessary action, (iii) are not and will not conflict with or result in any breach or contravention of, or the creation of any Lien under, any Material Contract to which any Credit Party is a party, any Organizational Document of any Credit Party, any order, injunction, writ or decree of any Governmental Authority or any arbitral award to which any Credit Party or the property of any Credit Party is subject, (iv) will not violate any applicable Law (including, without limitation, any corporation law, limited liability company law or partnership law of the states in which the Credit Parties are organized), and (v) will not result in a limitation on any material licenses, permits or other governmental approvals applicable to the business, operations or properties of any Credit Party.

(c)This Amendment and all allonges, assignments, instruments, documents, and agreements executed and delivered in connection herewith, are and will be valid, binding, and enforceable against each Credit Party in accordance with their respective terms, except as enforceability may be limited by bankruptcy, insolvency or other similar laws relating to the enforcement of creditors’ rights generally and by general equitable principles.

(d)No Event of Default or Default has occurred and is continuing as of the date of this Amendment.

(e)Both before and after giving effect to (a) the Loans to be made or extended on the date hereof, (b) the disbursement of the proceeds of such Loans pursuant to the instructions of the Credit Parties, (c) the consummation of the transactions contemplated in the Financing Documents, and (e) the payment and accrual of all transaction costs in connection with the foregoing, the Credit Parties, taken as a whole, are Solvent.

5.Conditions to Effectiveness.  The obligation of Agent and Lenders to enter into this Amendment shall be subject to the satisfaction of the following conditions precedent:

(a) that Agent shall have a copy of this Amendment, duly executed by Borrowers, Agent and each Lender, in form and substance satisfactory to Agent;

(b)that Agent shall have a copy of the corresponding amendment to the Affiliated Credit Agreement duly executed by the parties thereto, in form and substance satisfactory to Agent; and

(c)all fees payable to Agent or any Lender in connection with the execution of this Amendment shall have been paid.

6.Costs, Fees and Expenses.  In consideration of Agent’s and each Lender’s agreement to enter into this Amendment, Borrowers shall be responsible for the payment of all reasonable costs, fees and expenses of Agent’s counsel incurred in connection with the preparation of this Amendment and any related documents.  All such costs, fees and expenses shall be paid with proceeds of Revolving Loans.

 

4



 

7.Defenses and Setoffs.  Each Credit Party hereby represents and warrants that as of the date hereof, there are no defenses, setoffs, claims or counterclaims which could be asserted against the Agent or the Lenders arising from or in connection with the Credit Agreement or any other Financing Document.

8.Affirmation.  Except as specifically amended pursuant to the terms hereof, the Credit Agreement and all other Financing Documents (and all covenants, terms, conditions and agreements therein) shall remain in full force and effect, and are hereby ratified and confirmed in all respects by Borrowers.  Each Borrower covenants and agrees to comply with all of the terms, covenants and conditions of the Credit Agreement (as amended hereby) and the Financing Documents notwithstanding any prior course of conduct, waivers, releases or other actions or inactions on Agent’s or any Lender’s part which might otherwise constitute or be construed as a waiver of or agreement to such terms, covenants and conditions.

9.No Waiver or Novation.  The execution, delivery and effectiveness of this Amendment shall not operate as a waiver of any right, power or remedy of Agent or Lenders, nor constitute a waiver of any provision of the Credit Agreement, the other Financing Documents or any other documents, instruments and agreements executed or delivered in connection with any of the foregoing.  Nothing herein is intended or shall be construed as a waiver of any existing Defaults or Events of Default under the Credit Agreement or other Financing Documents or any of Agent’s or Lenders’ rights and remedies in respect of such Defaults or Events of Default.  This Amendment (together with any other document executed in connection herewith) is not intended to be, nor shall it be construed as, a novation of the Credit Agreement.

10.Incorporation of Credit Agreement Provisions.  The provisions contained in Section 12.8 (Governing Law; Submission to Jurisdiction) and 12.9 (Waiver of Jury Trial) of the Credit Agreement are incorporated herein by reference to the same extent as if reproduced herein in their entirety.

11.Headings.  Section headings in this Amendment are included for convenience of reference only and shall not constitute a part of this Amendment for any other purpose.

12.Counterparts.  This Amendment may be executed in counterparts, and such counterparts taken together shall be deemed to constitute one and the same instrument.  Signatures by facsimile or by electronic mail delivery of an electronic version of any executed signature page shall bind the parties hereto.

13.Reference to the Effect on the Financing Documents.  Upon the effectiveness of this Amendment, each reference in any Financing Document to “this Amendment,” “hereunder,” “hereof,” “herein” or words of similar import shall mean and be a reference to such Financing Document as modified by this Amendment.

(SIGNATURES APPEAR ON FOLLOWING PAGES)

 

 

 

5



 

IN WITNESS WHEREOF, intending to be legally bound, the undersigned have executed this Amendment as of the day and year first hereinabove set forth.

signature page to amendment no. 4 to credit and security agreement (revolver)



 

 


	
BORROWER
	
 
	
ACCURAY INCORPORATED
	
 

	
REPRESENTATIVE:
	
 
	
a Delaware corporation
	
 

	
 
	
 
	
 
	
 

	
 
	
 
	
By:
	
/s/ Shigeyuki Hamamatsu
	
 

	
 
	
 
	
 
	
Shigeyuki Hamamatsu
	
 

	
 
	
 
	
 
	
Chief Financial Officer
	
 




 

signature page to amendment no. 4 to credit and security agreement (revolver)



 

 


	
OTHER
	
 
	
TOMOTHERAPY INCORPORATED,
	
 

	
BORROWERS:
	
 
	
a Wisconsin corporation
	
 

	
 
	
 
	
 
	
 

	
 
	
 
	
By:
	
/s/ Shigeyuki Hamamatsu
	
 

	
 
	
 
	
 
	
Shigeyuki Hamamatsu
	
 

	
 
	
 
	
 
	
Director
	
 




 

signature page to amendment no. 4 to credit and security agreement (revolver)



 

 


	
AGENT:
	
 
	
MIDCAP FUNDING IV TRUST, a Delaware statutory trust

	
 
	
 
	
 

	
 
	
 
	
By:
	
 
	
Apollo Capital Management, L.P.

	
 
	
 
	
Its:
	
 
	
Investment Manager

	
 
	
 
	
 

	
 
	
 
	
 
	
By:
	
 
	
Apollo Capital Management GP, LLC

	
 
	
 
	
 
	
Its:
	
 
	
General Partner

	
 
	
 
	
 

	
 
	
 
	
 
	
By:
	
 
	
/s/ Maurice Amsellem

	
 
	
 
	
 
	
 
	
 
	
Maurice Amsellem

	
 
	
 
	
 
	
 
	
 
	
Authorized Signatory

	
 
	
 
	
 

	
LENDER:
	
 
	
MIDCAP FUNDING IV TRUST, a Delaware statutory trust

	
 
	
 
	
 

	
 
	
 
	
By:
	
 
	
Apollo Capital Management, L.P.

	
 
	
 
	
Its:
	
 
	
Investment Manager

	
 
	
 
	
 

	
 
	
 
	
 
	
By:
	
 
	
Apollo Capital Management GP, LLC

	
 
	
 
	
 
	
Its:
	
 
	
General Partner

	
 
	
 
	
 

	
 
	
 
	
 
	
By:
	
 
	
/s/ Maurice Amsellem

	
 
	
 
	
 
	
 
	
 
	
Maurice Amsellem

	
 
	
 
	
 
	
 
	
 
	
Authorized Signatory




 

 

 

signature page to amendment no. 4 to credit and security agreement (revolver)



 

Schedule 9.2

Location of Collateral

 


				
	
Company
	
Chief Executive Office
	
Chief Place of Business
	
Books and Records

	
Accuray Incorporated
	
1310 Chesapeake Terrace

Sunnyvale, CA 94089
	
1310 Chesapeake Terrace

Sunnyvale, CA 94089
	
1310 Chesapeake Terrace

Sunnyvale, CA 94089

1209 Deming Way

Madison, WI 53717

	
TomoTherapy

Incorporated
	
1310 Chesapeake Terrace

Sunnyvale, CA 94089
	
1310 Chesapeake Terrace

Sunnyvale, CA 94089
	
1310 Chesapeake Terrace

Sunnyvale, CA 94089

1209 Deming Way

Madison, WI 53717




 

Inventory by Location

 


	
Street

Address
	
City
	
State or

Country
	
Zip

Code
	
Nature of such

Location
	
Name and

address

of 3rd

party

warehouse

owning or

operating

that

location
	
Inventory

Balance as 

of

April 30,

2019

	
[*****]
	
[*****]
	
[*****]
	
[*****]
	
[*****]
	
[*****]
	
[*****]

	
[*****]
	
[*****]
	
[*****]
	
[*****]
	
[*****]
	
[*****]
	
[*****]

	
[*****]
	
[*****]
	
[*****]
	
[*****]
	
[*****]
	
[*****]
	
[*****]

	
[*****]
	
[*****]
	
[*****]
	
 
	
[*****]
	
[*****]
	
[*****]

	
[*****]
	
[*****]
	
[*****]
	
 
	
[*****]
	
[*****]
	
[*****]

	
[*****]
	
[*****]
	
[*****]
	
[*****]
	
[*****]
	
[*****]
	
[*****]

	
[*****]
	
[*****]
	
[*****]
	
[*****]
	
[*****]
	
[*****]
	
[*****]

	
[*****]
	
[*****]
	
[*****]
	
[*****]
	
[*****]
	
[*****]
	
[*****]

	
[*****]
	
 
	
[*****]
	
 
	
[*****]
	
[*****]
	
[*****]

	
[*****]
	
 
	
 
	
 
	
 
	
 
	
 

	
[*****]
	
[*****]
	
[*****]
	
[*****]
	
[*****]
	
[*****]
	
[*****]

	
[*****]
	
[*****]
	
[*****]
	
[*****]
	
[*****]
	
[*****]
	
[*****]

	
[*****]
	
[*****]
	
[*****]
	
[*****]
	
[*****]
	
[*****]
	
[*****]

	
[*****]
	
[*****]
	
[*****]
	
[*****]
	
[*****]
	
[*****]
	
[*****]




 


			
	
 
	
Schedule 9.2
	
 




[*****] Asterisks indicate that confidential information has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to this omitted information.



 


	
[*****]
	
[*****]
	
[*****]
	
[*****]
	
[*****]
	
[*****]
	
[*****]

	
[*****]
	
[*****]
	
[*****]
	
[*****]
	
[*****]
	
[*****]
	
[*****]

	
[*****]
	
[*****]
	
[*****]
	
[*****]
	
[*****]
	
[*****]
	
[*****]

	
[*****]
	
[*****]
	
[*****]
	
[*****]
	
[*****]
	
[*****]
	
[*****]

	
[*****]
	
[*****]
	
[*****]
	
[*****]
	
[*****]
	
[*****]
	
[*****]

	
[*****]
	
[*****]
	
[*****]
	
[*****]
	
[*****]
	
[*****]
	
[*****]

	
[*****]
	
[*****]
	
[*****]
	
[*****]
	
[*****]
	
[*****]
	
[*****]

	
[*****]
	
[*****]
	
[*****]
	
[*****]
	
[*****]
	
[*****]
	
[*****]

	
[*****]
	
 
	
 
	
 
	
 
	
 
	
 

	
[*****]
	
[*****]
	
[*****]
	
 
	
[*****]
	
[*****]
	
[*****]

	
[*****]
	
[*****]
	
[*****]
	
 
	
[*****]
	
[*****]
	
[*****]

	
[*****]
	
[*****]
	
[*****]
	
 
	
[*****]
	
[*****]
	
[*****]

	
[*****]
	
[*****]
	
[*****]
	
 
	
[*****]
	
[*****]
	
[*****]

	
[*****]
	
[*****]
	
[*****]
	
 
	
[*****]
	
[*****]
	
[*****]

	
[*****]
	
[*****]
	
[*****]
	
 
	
[*****]
	
[*****]
	
[*****]

	
[*****]
	
[*****]
	
[*****]
	
 
	
[*****]
	
[*****]
	
[*****]

	
[*****]
	
[*****]
	
[*****]
	
 
	
[*****]
	
[*****]
	
[*****]

	
[*****]
	
[*****]
	
[*****]
	
 
	
[*****]
	
[*****]
	
[*****]

	
[*****]
	
[*****]
	
[*****]
	
 
	
[*****]
	
[*****]
	
[*****]

	
[*****]
	
[*****]
	
[*****]
	
 
	
[*****]
	
[*****]
	
[*****]

	
[*****]
	
[*****]
	
[*****]
	
 
	
[*****]
	
[*****]
	
[*****]

	
[*****]
	
[*****]
	
[*****]
	
 
	
[*****]
	
[*****]
	
[*****]

	
[*****]
	
[*****]
	
[*****]
	
 
	
[*****]
	
[*****]
	
[*****]

	
[*****]
	
 
	
 
	
 
	
 
	
 
	
 

	
[*****]
	
[*****]
	
[*****]
	
 
	
[*****]
	
[*****]
	
[*****]

	
[*****]
	
 
	
 
	
 
	
[*****]
	
[*****]
	
[*****]

	
[*****]
	
 
	
 
	
 
	
[*****]
	
[*****]
	
[*****]

	
[*****]
	
 
	
 
	
 
	
[*****]
	
[*****]
	
[*****]

	
[*****]
	
 
	
 
	
 
	
[*****]
	
[*****]
	
[*****]

	
 
	
 
	
 
	
 
	
 
	
Grand

Total
	
[*****]




 


			
	
 
	
Schedule 9.2
	
 




[*****] Asterisks indicate that confidential information has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to this omitted information.



 

[*****]

 


	
Row Labels
	
Sum of Netbook (USD)
	
 
	
 

	
[*****]
	
[*****]
	
 
	
[*****]

	
[*****]
	
[*****]
	
 
	
[*****]

	
[*****]
	
[*****]
	
 
	
[*****]

	
[*****]
	
[*****]
	
 
	
[*****]

	
[*****]
	
[*****]
	
 
	
 

	
[*****]
	
[*****]
	
 
	
 

	
[*****]
	
[*****]
	
 
	
 

	
[*****]
	
[*****]
	
 
	
 

	
[*****]
	
[*****]
	
 
	
[*****]

	
[*****]
	
[*****]
	
 
	
[*****]

	
[*****]
	
[*****]
	
 
	
 

	
[*****]
	
[*****]
	
 
	
[*****]

	
[*****]
	
[*****]
	
 
	
[*****]

	
[*****]
	
[*****]
	
 
	
[*****]

	
[*****]
	
[*****]
	
 
	
[*****]

	
[*****]
	
[*****]
	
 
	
[*****]

	
[*****]
	
[*****]
	
 

	
[*****]
	
[*****]
	
 

	
[*****]
	
[*****]
	
 

	
[*****]
	
[*****]
	
 

	
[*****]
	
[*****]
	
 

	
[*****]
	
[*****]
	
 

	
[*****]
	
[*****]
	
 

	
[*****]
	
[*****]
	
 

	
[*****]
	
[*****]
	
 

	
[*****]
	
[*****]
	
 
	
 

	
 

	
[*****]
	
[*****]
	
 

	
[*****]
	
[*****]
	
[*****]

	
[*****]
	
[*****]
	
 

	
[*****]
	
[*****]
	
 

	
[*****]
	
[*****]
	
 

	
[*****]
	
[*****]
	
 

	
[*****]
	
[*****]
	
 

	
[*****]
	
[*****]
	
 

	
[*****]
	
[*****]
	
 

	
[*****]
	
[*****]
	
 

	
[*****]
	
[*****]
	
 

	
[*****]
	
[*****]
	
 




 


			
	
 
	
Schedule 9.2
	
 




[*****] Asterisks indicate that confidential information has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to this omitted information.



 


	
[*****]
	
[*****]
	
 

	
[*****]
	
[*****]
	
 

	
[*****]
	
[*****]
	
 

	
[*****]
	
[*****]
	
 

	
[*****]
	
[*****]
	
 

	
[*****]
	
[*****]
	
 

	
[*****]
	
[*****]
	
 

	
[*****]
	
[*****]
	
 
	
 

	
[*****]
	
[*****]
	
 
	
 

	
[*****]
	
[*****]
	
 
	
[*****]

	
[*****]
	
[*****]
	
 
	
 

	
[*****]
	
[*****]
	
 
	
[*****]

	
[*****]
	
[*****]
	
 
	
[*****]

	
[*****]
	
[*****]
	
 
	
 

	
[*****]
	
[*****]
	
 
	
[*****]

	
[*****]
	
[*****]
	
 
	
 

	
[*****]
	
[*****]
	
 
	
[*****]

	
[*****]
	
[*****]
	
 
	
[*****]

	
[*****]
	
[*****]
	
 
	
 

	
[*****]
	
[*****]
	
 
	
 

	
[*****]
	
[*****]
	
 
	
[*****]

	
[*****]
	
[*****]
	
 
	
 

	
Grand Total
	
$ [*****]
	
 
	
 




 

[*****]

 


	
Row Labels
	
Sum of Ending Bal
	
 

	
[*****]
	
[*****]
	
 

	
[*****]
	
[*****]
	
 

	
[*****]
	
[*****]
	
 

	
[*****]
	
[*****]
	
 

	
[*****]
	
[*****]
	
 

	
Grand Total
	
 $ [*****]
	
 




 

 


			
	
 
	
Schedule 9.2
	
 




[*****] Asterisks indicate that confidential information has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to this omitted information.